Cencora announced a notable 15% price increase over the last quarter, which coincided with substantial financial improvements as reported in its latest earnings release. The company reported growth in both sales and income, with second-quarter sales rising to $75.5 billion and net income increasing to $718 million, highlighting a strong performance compared to last year. Alongside this, the declaration of a quarterly cash dividend of $0.55 per common share likely reinforced investor confidence. These positive financial developments and shareholder returns were supportive of Cencora's price climb amid a mixed broader market.

Every company has risks, and we've spotted 4 weaknesses for Cencora (of which 2 are a bit concerning!) you should know about.NYSE:COR Earnings Per Share Growth as at May 2025

Diversify your portfolio with solid dividend payers offering reliable income streams to weather potential market turbulence.

Cencora's recent 15% share price increase aligns with its robust financial performance and the declaration of a quarterly US$0.55 dividend. Over the longer five-year period, Cencora's total shareholder return was an impressive 249.71%. This contrasted sharply with the past year's performance, where Cencora outperformed the US Healthcare industry, which saw a 9.6% decline. This contrast highlights the company's resilience and ability to deliver substantial long-term gains for investors.

The news of increased earnings and a strengthening balance sheet could positively influence Cencora's revenue and earnings forecasts. As Cencora expands its footprint through acquisitions like Retina Consultants of America and OneOncology, these initiatives may bolster its specialty pharma leadership and global reach, potentially boosting future revenues. However, increased GLP-1 sales and decreased COVID-19 vaccine sales could place pressure on margins.

In terms of valuation, the current share price of US$290.17 remains close to the consensus analyst price target of US$297.49, suggesting limited short-term upside. Analysts' expectations for a PE ratio adjustment to 21.5x by 2028 indicate that, while the company may be fairly priced now, potential growth prospects, if realized, could justify a higher future valuation. Investors should consider weighing these growth opportunities against current market conditions and industry trends.

Understand Cencora's track record by examining our performance history report.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.

Story Continues

Companies discussed in this article include NYSE:COR.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email [email protected]